Telix Pharmaceuticals (Innovations) Pty Limited
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-36
RECRUITING4
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO60%
Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +7.0 months). See all sponsors →
Open Telix Pharmaceuticals (Innovations) Pty Limited on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| 89Zr-TLX250 PET/CT NCT06750419 |
P3 | Recruiting | Clear Cell Renal Cell Carcinoma | 82 | 2026-06-30 |
| BiPASS NCT07052214 |
P3 | Active, not recruiting | PCA; Prostate Cancer | 338 | 2027-01 (+7 mo) |
| LUTEON NCT07197580 |
P3 | Recruiting | ccRCC; Renal Cell Carcinoma (Kidney Cancer) | 40 | 2027-08-31 (+8 mo) |
| 177Lu-TLX591 NCT06520345 |
P3 | Recruiting | Metastatic Castration-resistant Prostate Cancer | 520 | 2027-12 |
| TLX101-Px NCT07931261 |
P3 | Not yet recruiting | Brain Metastasis; Radiation Necrosis | 381 | 2028-04 |
| IPAX BrIGHT NCT07100730 |
P3 | Recruiting | Neoplastic Disease; Glioblastoma | 51 | 2028-07 (+12 mo) |
| LUTEON ATLAS NCT07870746 |
P2 | Not yet recruiting | ccRCC; Renal Cell Carcinoma (Kidney Cancer) | 40 | 2028-12-31 |